Apellis Pharmaceuticals Inc. (NASDAQ:APLS) finished Friday with an addition of $0.19 to close at $51.71, an upside of 0.37 percent. An average of 793,320 shares of common stock have been traded in the last five days. There was a gain of $0.03 in the past week, and it reached a new high 18 times over the past 12 months. The last 20 days have seen an average of 964,195 shares traded, while the 50-day average volume stands at 1,371,390.
APLS stock has increased by 3.56% in the last month. The company shares reached their 1-month lowest point of $46.57 on 12/07/22. With the stock rallying to its 52-week high on 09/09/22, shares of the company touched a low of $33.32 and a high of $70.00 in 52 weeks. It has reached a new high 17 times so far this year and achieved 9.37% or $4.43 in price. In spite of this, the price is down -26.13% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
APLS stock investors should be aware that Apellis Pharmaceuticals Inc. (APLS) stock had its last reported insider trading activity 12 days ago on Dec 19. In this transaction, the insider spent $1,467,983. Director, Machiels Alec, disposed of 1,250 shares at a price of $52.35 on Dec 15. The insider now owns more than $65,438 worth of shares. Prior to that, Chief Scientific Officer Deschatelets Pascal went on to Sale 12,000 shares at $47.50 each on Dec 08. An amount of $570,000 was transacted.
Apellis Pharmaceuticals Inc. (APLS) stock’s beta is 1.14. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 51.42, the price-to-book (PB) ratio at 18.34.
The quick ratio of Apellis Pharmaceuticals Inc. for the three months ended June 29 was 6.70, and the current ratio was 7.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.41 and a total debt to equity ratio of 1.46 for the quarter ending June 29. Its gross profit as reported stood at -$13.64 million compared to revenue of $66.56 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Apellis Pharmaceuticals Inc.’s return on assets was -65.00%.
For the three-month period that ended June 29, Apellis Pharmaceuticals Inc. had $124.36 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$191.27 million in the quarter, while revenues of -$155.98 million were shrunk -2.25%. The analyst consensus anticipated Apellis Pharmaceuticals Inc.’s latest quarter earnings to come in at -$1.36 per share, but it turned out to be -$1.46, a -7.40% surprise. For the quarter, EBITDA amounted to -$132.43 million. Shareholders own equity worth $110.58 million.
From a technical analysis perspective, let’s take a brief look at Apellis Pharmaceuticals Inc. (APLS) price momentum. RSI 9-day as of the close on 30 December was 54.09%, suggesting the stock is Neutral, with historical volatility in this time frame at 32.16%.
As of today, APLS’s price is $50.56 +0.06% or $0.03 from its 5-day moving average. APLS is currently trading +3.86% higher than its 20-day SMA and -19.57% lower than its 100-day SMA. However, the stock’s current price level is -9.42% below the SMA50 and +14.30% above the SMA200.
The stochastic %K and %D were 48.91% and 44.21%, respectively, and the average true range (ATR) was 2.17. With the 14-day stochastic at 55.92% and the average true range at 2.41, the RSI (14) stands at 51.96%. The stock has reached -0.33 on the 9-day MACD Oscillator while the 14-day reading was at -0.81.
Jefferies downgraded Apellis Pharmaceuticals Inc. (NASDAQ: APLS) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Apellis Pharmaceuticals Inc. (APLS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell APLS, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 13 others rate it as a “buy”.
What is APLS’s price target for the next 12 months?
Analysts predict a range of price targets between $40.00 and $123.00, with a median target of $77.00. Taking a look at these predictions, the average price target given by analysts for Apellis Pharmaceuticals Inc. (APLS) stock is $76.38.